Localized, Implantable mRNA Vaccine Depots Using Smart Biomaterials

The Expert Opinion on Drug Delivery review (Chen et al., 2024) points out the value of biomaterials in cancer vaccine delivery, but most efforts to date focus on systemic, single-bolus administration. What if we leverage advances in smart, biodegradable hydrogels or microneedle arrays to create localized depots that release mRNA (and/or adjuvants) in a tunable manner over weeks or months? This could maintain high local antigen concentration at the injection site, enhance immune cell activation, and reduce systemic side effects—potentially making “single-shot” or even self-boosting vaccines a reality. For cancer, such depots could be implanted in the tumor bed or draining lymph nodes for personalized, localized immunotherapy. This approach synthesizes biomaterials science with mRNA vaccine technology, representing a tangible step beyond current LNP systemic delivery models and opening up new avenues for both infectious disease prevention and cancer treatment.

References:

1. Biomaterials-assisted cancer vaccine delivery: preclinical landscape, challenges, and opportunities. Minglong Chen, Yue Zhou, Yanping Fu, Qingqing Wang, Chuanbin Wu, Xin Pan, Guilan Quan (2024). Expert Opinion on Drug Delivery.